CAS 1185763-69-2

Formula: C20H16N6

InChI: InChI=1S/C20H16N6/c1-25-13-16(11-23-25)19-6-7-20-22-12-17(26(20)24-19)10-14-4-5-18-15(9-14)3-2-8-21-18/h2-9,11-13H,10H2,1H3

InChI key: RNCNPRCUHHDYPC-UHFFFAOYSA-N

SMILES: CN1C=C(C=N1)C2=NN3C(=NC=C3CC4=CC5=C(C=C4)N=CC=C5)C=C2

NVP-BVU 972

CAS: 1185763-69-2

Formula: C₂₀H₁₆N₆

Purity: 98%

Color and Shape: Solid

Molecular weight: 340.3812

Ref: IN-DA008TIM

NVP-BVU972

CAS: 1185763-69-2

NVP-BVU972

Formula: C₂₀H₁₆N₆

Purity: ≥95%

Molecular weight: 340.38

Ref: 54-BUP07800

NVP-BVU972

CAS: 1185763-69-2

6-((6-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-b]pyridazin-3-yl)methyl)quinoline

Formula: C₂₀H₁₆N₆

Purity: 98%

Molecular weight: 340.38

Ref: IN-DG559124

NVP-BVU972

CAS: 1185763-69-2

NVP-BVU972 is a selective and potent Met inhibitor with IC50 of 14 nM.

Formula: C₂₀H₁₆N₆

Purity: 97.24% - >99.99%

Color and Shape: Solid

Molecular weight: 340.38

Ref: TM-T2680

NVP-BVU972

CAS: 1185763-69-2

NVP-BVU972 is a small molecule inhibitor of the tyrosine kinase activity of the epidermal growth factor receptor. It has been shown to inhibit the growth of cancer cells in vitro and in vivo. NVP-BVU972 binds to the ATP binding site of the kinase domain and inhibits protein synthesis by preventing phosphorylation of downstream substrates. This drug also has a pharmacokinetic profile that is not affected by renal or hepatic dysfunction. NVP-BVU972 is currently being evaluated as a predictive biomarker for cancer treatment response.

Formula: C₂₀H₁₆N₆

Purity: Min. 95%

Molecular weight: 340.39 g/mol

Ref: 3D-KXB76369